NZ600010A - Novel crystalline forms of bosentan, processes for their preparation and uses thereof - Google Patents

Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Info

Publication number
NZ600010A
NZ600010A NZ600010A NZ60001008A NZ600010A NZ 600010 A NZ600010 A NZ 600010A NZ 600010 A NZ600010 A NZ 600010A NZ 60001008 A NZ60001008 A NZ 60001008A NZ 600010 A NZ600010 A NZ 600010A
Authority
NZ
New Zealand
Prior art keywords
bosentan
processes
preparation
crystalline forms
novel crystalline
Prior art date
Application number
NZ600010A
Other languages
English (en)
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Prakash Bansode
Dattatraya Shinde
Sunanda Phadtare
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of NZ600010A publication Critical patent/NZ600010A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ600010A 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof NZ600010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2108MU2007 2007-10-24
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Publications (1)

Publication Number Publication Date
NZ600010A true NZ600010A (en) 2013-11-29

Family

ID=40262729

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Country Status (8)

Country Link
US (1) US8530488B2 (OSRAM)
EP (1) EP2222649A2 (OSRAM)
JP (1) JP2011500780A (OSRAM)
CN (1) CN101939303B (OSRAM)
AU (1) AU2008315757A1 (OSRAM)
CA (1) CA2703230A1 (OSRAM)
NZ (2) NZ600010A (OSRAM)
WO (1) WO2009053748A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135795A2 (en) * 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) * 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
US8481730B2 (en) 2008-01-01 2013-07-09 Cipla Limited Method of synthesis of Bosentan, its polymorphic forms and its salts
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
AU2009211159B2 (en) 2008-02-08 2013-02-07 Generics [Uk] Limited Process for preparing bosentan
US20110263623A1 (en) 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
AU2009321375A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited HPLC method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
SI1235799T1 (en) 1999-11-17 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
HRP20050176A2 (en) 1999-12-16 2005-08-31 Teva Pharmaceutical Industries Ltd. Novel processes for making - and a new crystalline form of-leflunomide
ATE316963T1 (de) * 2000-01-25 2006-02-15 Hoffmann La Roche Herstellung von sulfonamiden
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
WO2008122020A1 (en) * 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
WO2008135795A2 (en) 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) * 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
EP2072503B1 (en) 2007-12-18 2011-10-26 Dipharma Francis S.r.l. Process for the preparation of bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
AU2009211159B2 (en) 2008-02-08 2013-02-07 Generics [Uk] Limited Process for preparing bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
AU2009321375A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited HPLC method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
JP2011500780A (ja) 2011-01-06
EP2222649A2 (en) 2010-09-01
WO2009053748A3 (en) 2009-06-18
CA2703230A1 (en) 2009-04-30
US20100331352A1 (en) 2010-12-30
NZ585438A (en) 2012-09-28
CN101939303A (zh) 2011-01-05
AU2008315757A1 (en) 2009-04-30
US8530488B2 (en) 2013-09-10
CN101939303B (zh) 2014-06-11
WO2009053748A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
NZ600010A (en) Novel crystalline forms of bosentan, processes for their preparation and uses thereof
Ludovici et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues
DE69615085T2 (de) Sulfonamide Derivate und Verfahren zu deren Herstellung
CL2013000372A1 (es) Compuestos derivados de 1-fenil(dihidropirimidina/pirimidina)-2,4(1h,3h)-diona; forma cristalina de n-(6-(3-tert-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il-metoxifenil)naftalen-2-il)metansulfonamida; proceso de preparacion;composicion farmaceutica; y su uso como antiviral para vhc (divisional cl 2794-08)
GEP20105073B (en) Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
NO20076325L (no) Dispersible bosertan tablet
CN101914065A (zh) 有助于治疗由crth2介导的疾病的嘧啶衍生物
HRP20050780A2 (hr) Novitetni kvinolin, tetrahidrokvinazolin i derivati pirimidina, kao i metode tretmana koji se povezani s njihovim korištenjem
TW200602058A (en) Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives
WO2008060621A3 (en) Aminopyrrolidines as chemokine receptor antagonists
SI2509963T1 (sl) Kristalinične oblike 3-(2,6-dikloro-3,5-dimetoksi-fenil)-1-(6-(4-4-etil-piperazin-1-il)- fenilamino)-pirimidin-4-il)-1-metil-uree in njenih soli
ATE274510T1 (de) Glycogen synthase kinase 3 inhibitoren
WO2009016253A3 (en) Cyanomethyl substituted n-acyl tryptamines
EP4275754A3 (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
AU2010251943A1 (en) 2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
WO2009080721A3 (en) 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists
MX2022013804A (es) Polimorfos de moduladores de los receptores de pirimidin-ciclohexil-glucocorticoides.
EP2584901A4 (en) PROCESS FOR PREPARING THE INTERMEDIATE OF STRAIN AND STRAIN OF POLYMORPHS
WO2006133242A3 (en) Azinone and diazinone v3 inhibitors for depression and stress disorders
WO2009013171A3 (en) Heterocyclic antiviral compounds
EP4520337A3 (en) Oligonucleotides comprising modified nucleosides
WO2006135839A3 (en) Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
UA106724C2 (uk) Спосіб отримання заміщених піримідинових похідних
FR2884511B1 (fr) Procede de production de fines particules d'alpha-alumine et de fines particules d'un compose metallique, et fines particules ainsi obtenues

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed